Pfizer PT Raised to $34.00 at JPMorgan Chase & Co. (PFE)
Investment analysts at JPMorgan Chase & Co. upped their price target on shares of Pfizer (NYSE:PFE) from $33.00 to $34.00 in a note issued to investors on Friday, American Banking and Market News reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 17.73% from the stock’s previous close.
Pfizer (NYSE:PFE) traded up 1.26% during mid-day trading on Friday, hitting $28.88. The stock had a trading volume of 28,205,304 shares. Pfizer has a 52 week low of $23.55 and a 52 week high of $31.15. The stock’s 50-day moving average is $28.54 and its 200-day moving average is $28.83. The company has a market cap of $191.2 billion and a price-to-earnings ratio of 7.91.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was down 7.1% on a year-over-year basis.
In other Pfizer news, EVP Freda Lewis-Hall sold 38,461 shares of the stock on the open market in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $28.70, for a total value of $1,103,830.70. Following the sale, the executive vice president now directly owns 118,383 shares in the company, valued at approximately $3,397,592. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of other analysts have also recently weighed in on PFE. Analysts at Jefferies Group cut their price target on shares of Pfizer (NYSE:PFE) from $31.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Pfizer (NYSE:PFE) to $28.50 in a research note to investors on Tuesday, September 3rd. They now have a “market perform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer (NYSE:PFE) in a research note to investors on Monday, September 2nd. They now have a $30.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and a consensus target price of $30.55.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.